Ulcerative Colitis Treatment Market Size Share Growth and Report 2023-2030

Global Ulcerative Colitis Treatment Market Sets to Expand, Projected to Reach US$ 11.1 Billion by 2030

The global ulcerative colitis treatment market, valued at US$ 6.9 billion in 2022, is poised for substantial growth, projected to attain US$ 11.1 billion by 2030. This growth is anticipated to be fueled by a robust compound annual growth rate (CAGR) of 6.3% during the forecast period from 2023 to 2030.

Market Dynamics Driving Growth

A surge in inflammatory bowel diseases, specifically ulcerative colitis, is contributing to the market's upward trajectory. Factors such as intensified research activities, a rise in product approvals, and notable market developments, including mergers, acquisitions, collaborations, and product introductions, are key drivers of the global ulcerative colitis treatment market.

Market Scope and Metrics

CAGR: 6.3%
Size Available for Years: 2021-2030
Forecast Period: 2023-2030
Data Availability: Value (US$)
Segments Covered: Type, Drug Class, Route of Administration, Distribution Channel, and Region
Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Download Sample: https://www.datamintelligence.com/download-sample/ulcerative-colitis-treatment-market

Market Insights and Analysis

Increasing Market Developments Boost Market Growth

Market developments, exemplified by Pfizer's acquisition of Arena Pharmaceuticals in March 2022, are expected to be a catalyst for market growth. This strategic move aimed to leverage Arena Pharmaceuticals' pipeline in conjunction with Pfizer's Immunology and swelling healing domain.

Research Activities Present Growth Opportunities

A surge in research activities, as seen with Takeda Pharmaceutical's phase III clinical investigation for intravenous Vedolizumab, is presenting substantial growth opportunities. The investigation aims to evaluate the effectiveness and safety of the drug in Japanese individuals with moderate to severe ulcerative colitis.

Stringent Regulatory Bodies Pose Challenges

However, the presence of stringent regulatory bodies, including the United States Food and Drug Administration (USFDA) and the European Medicines Agency, is anticipated to pose challenges for market growth during the forecast period.

Segment Analysis

Immunosuppressant Drug Class Dominates Market

The immunosuppressant drug class segment is estimated to dominate the global ulcerative colitis treatment market, holding approximately 39.6% of the market share. Bristol Myers Squibb's marketing authorization for Zeposia in November 2021 is a notable contributor to the segment's dominance.

Geographical Share

North America Holds Prominent Market Share

Owing to a high prevalence of inflammatory bowel diseases, North America is estimated to hold around 38.8% of the global market share by 2030. Pfizer's promising topline results from a Phase 3 investigation of stasimon further contribute to regional growth.

Key Market Players

The major global players in the ulcerative colitis treatment market include Abbott Laboratories, Ajinomoto, AstraZeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi, among others.

For More Insights: https://www.datamintelligence.com/research-report/ulcerative-colitis-treatment-market

Market Segmentation

By Type:

Ulcerative Proctitis
Proctosigmoiditis
Left-sided Colitis
Pancolitis or Universal Colitis
Fulminant Colitis
By Drug Class:

Immunosuppressant
Anti-Inflammatory Drugs
Anti-TNF biologics
Calcineurin Inhibitors
Other
By Route of Administration:

Oral
Injectables
By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:

North America
Europe
South America
Asia-Pacific
Middle East and Africa

Related Reports:

Achalasia Treatment Market: https://www.datamintelligence.com/research-report/achalasia-treatment-market

Esomeprazole Market: https://www.datamintelligence.com/research-report/esomeprazole-market

Antiemetic Drugs Market: https://www.datamintelligence.com/research-report/antiemetic-drugs-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.